|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
CA2896083A1
(en)
|
2005-12-08 |
2007-06-14 |
Insmed Incorporated |
Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
|
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
|
DK2180787T3
(da)
|
2007-08-01 |
2014-02-03 |
Univ Pittsburgh |
Nitrooliesyremodulering af type ii-diabetes
|
|
CA2710713C
(en)
|
2007-12-27 |
2017-09-19 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
|
WO2009127060A1
(en)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
JP2011519373A
(ja)
|
2008-05-01 |
2011-07-07 |
コンプレクザ インコーポレイテッド |
ビニル置換脂肪酸
|
|
EP2299997A4
(en)
|
2008-06-19 |
2012-01-11 |
Univ Utah Res Found |
USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
|
|
US20140024713A1
(en)
|
2008-06-19 |
2014-01-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
|
ES2475065T3
(es)
*
|
2008-10-09 |
2014-07-10 |
Tekmira Pharmaceuticals Corporation |
Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos
|
|
AU2015249072C1
(en)
*
|
2008-10-20 |
2022-10-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
MX2011004268A
(es)
*
|
2008-10-20 |
2011-06-01 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion de transtiretina.
|
|
JP6087504B2
(ja)
|
2008-11-07 |
2017-03-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
アミノアルコールリピドイドおよびその使用
|
|
WO2010054384A1
(en)
|
2008-11-10 |
2010-05-14 |
Alnylam Pharmaceuticals, Inc. |
Lipids and compositions for the delivery of therapeutics
|
|
ES2993911T3
(en)
*
|
2008-11-10 |
2025-01-13 |
Arbutus Biopharma Corp |
Novel lipids and compositions for the delivery of therapeutics
|
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
|
AU2010208035B2
(en)
*
|
2009-01-29 |
2016-06-23 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
|
NZ594995A
(en)
*
|
2009-03-12 |
2013-06-28 |
Alnylam Pharmaceuticals Inc |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
|
|
WO2010129687A1
(en)
*
|
2009-05-05 |
2010-11-11 |
Alnylam Pharmaceuticals, Inc |
Methods of delivering oligonucleotides to immune cells
|
|
DK3431076T3
(da)
*
|
2009-06-10 |
2021-12-20 |
Arbutus Biopharma Corp |
Forbedret lipidformulering
|
|
KR20120050429A
(ko)
*
|
2009-06-15 |
2012-05-18 |
알닐람 파마슈티칼스 인코포레이티드 |
Ｐｃｓｋ9 유전자를 표적으로 하는 지질 제형된 ｄｓｒｎａ
|
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
|
EP2449106B1
(en)
|
2009-07-01 |
2015-04-08 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
US9066902B2
(en)
|
2009-07-31 |
2015-06-30 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Fatty acids as anti-inflammatory agents
|
|
US9181295B2
(en)
|
2009-08-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
Cationic lipids with various head groups for oligonucleotide delivery
|
|
WO2011038160A2
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
WO2011041639A2
(en)
|
2009-10-02 |
2011-04-07 |
Miller Raymond A |
Heteroatom containing substituted fatty acids
|
|
WO2011056883A1
(en)
|
2009-11-03 |
2011-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
|
|
SI3338765T1
(sl)
|
2009-12-01 |
2019-05-31 |
Translate Bio, Inc. |
Derivat steroida za dostavo MRNA pri humanih genetskih boleznih
|
|
US8846631B2
(en)
*
|
2010-01-14 |
2014-09-30 |
Regulus Therapeutics Inc. |
MicroRNA compositions and methods
|
|
US9670487B2
(en)
|
2010-01-22 |
2017-06-06 |
Sirna Therapeutics, Inc. |
Cationic lipids for oligonucleotide delivery
|
|
EP2558074B1
(en)
|
2010-04-08 |
2018-06-06 |
The Trustees of Princeton University |
Preparation of lipid nanoparticles
|
|
US20130129811A1
(en)
*
|
2010-04-28 |
2013-05-23 |
Takeshi Kuboyama |
Cationic lipid
|
|
EP2567951B1
(en)
*
|
2010-04-28 |
2018-09-19 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
|
US20130123338A1
(en)
*
|
2010-05-12 |
2013-05-16 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
WO2011141703A1
(en)
*
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
|
JP2013531634A
(ja)
|
2010-05-24 |
2013-08-08 |
メルク・シャープ・エンド・ドーム・コーポレイション |
オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
|
|
CN103096875B
(zh)
|
2010-06-03 |
2016-08-17 |
阿尔尼拉姆医药品有限公司 |
用于递送活性剂的生物可降解脂质
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
PT2591114T
(pt)
|
2010-07-06 |
2016-08-02 |
Glaxosmithkline Biologicals Sa |
Imunização de mamíferos de grande porte com doses baixas de arn
|
|
EP3243526B1
(en)
|
2010-07-06 |
2019-11-27 |
GlaxoSmithKline Biologicals S.A. |
Delivery of rna to trigger multiple immune pathways
|
|
EP2590626B1
(en)
|
2010-07-06 |
2015-10-28 |
GlaxoSmithKline Biologicals SA |
Liposomes with lipids having an advantageous pka-value for rna delivery
|
|
HRP20161352T1
(hr)
|
2010-07-06 |
2016-12-02 |
Glaxosmithkline Biologicals Sa |
Čestice nalik na virione za unos samoreplicirajućih molekula rna
|
|
WO2012016184A2
(en)
*
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP4079856A1
(en)
|
2010-08-17 |
2022-10-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
|
EP2609135A4
(en)
|
2010-08-26 |
2015-05-20 |
Massachusetts Inst Technology |
POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
|
|
US9233997B2
(en)
|
2010-08-26 |
2016-01-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
|
|
EP3406730B1
(en)
|
2010-08-31 |
2022-02-23 |
Sirna Therapeutics, Inc. |
Novel single chemical entities and methods for delivery of oligonucleotides
|
|
PL4066857T3
(pl)
|
2010-08-31 |
2023-03-20 |
Glaxosmithkline Biologicals Sa |
Pegylowane liposomy do dostarczania rna kodującego immunogen
|
|
WO2012031205A2
(en)
|
2010-09-03 |
2012-03-08 |
The Brigham And Women's Hospital, Inc. |
Lipid-polymer hybrid particles
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
EP3943114B1
(en)
|
2010-09-20 |
2024-08-07 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cationic lipids for oligonucleotide delivery
|
|
AU2011307277A1
(en)
|
2010-09-30 |
2013-03-07 |
Merck Sharp & Dohme Corp. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
SI3590949T1
(sl)
|
2010-10-01 |
2022-09-30 |
Modernatx, Inc. |
Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe
|
|
CA2814386C
(en)
|
2010-10-11 |
2019-08-20 |
Novartis Ag |
Antigen delivery platforms
|
|
JP2013545727A
(ja)
|
2010-10-21 |
2013-12-26 |
メルク・シャープ・アンド・ドーム・コーポレーション |
オリゴヌクレオチド送達用の新規低分子量カチオン性脂質
|
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
|
DK2635265T3
(en)
|
2010-11-05 |
2018-07-16 |
Sirna Therapeutics Inc |
New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
CA2831392C
(en)
|
2011-03-28 |
2020-04-28 |
Massachusetts Institute Of Technology |
Conjugated lipomers and uses thereof
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
WO2012170930A1
(en)
|
2011-06-08 |
2012-12-13 |
Shire Human Genetic Therapies, Inc |
Lipid nanoparticle compositions and methods for mrna delivery
|
|
CA2838063C
(en)
|
2011-06-08 |
2023-07-11 |
Shire Human Genetic Therapies, Inc. |
Cleavable lipids
|
|
CN103764121A
(zh)
|
2011-07-06 |
2014-04-30 |
诺华股份有限公司 |
用于递送rna分子的具有有用n:p比的脂质体
|
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
EP2744491B1
(en)
|
2011-08-19 |
2020-07-29 |
The University of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
|
US9126966B2
(en)
*
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
US9271952B2
(en)
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
|
KR102272498B1
(ko)
|
2011-10-27 |
2021-07-06 |
메사추세츠 인스티튜트 오브 테크놀로지 |
약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
|
|
IN2014CN03463A
(enExample)
*
|
2011-11-18 |
2015-10-09 |
Alnylam Pharmaceuticals Inc |
|
|
JP6305343B2
(ja)
|
2011-12-07 |
2018-04-04 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
WO2013086354A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
RU2649364C2
(ru)
|
2011-12-16 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
US20130197205A1
(en)
|
2012-01-27 |
2013-08-01 |
Hoffmann-La Roche Inc. |
Chitosan covalently linked with small molecule integrin antagonist for targeted delivery
|
|
MX351015B
(es)
|
2012-01-27 |
2017-09-28 |
Hoffmann La Roche |
Conjugados de antagonista de la integrina para su suministro dirigido a celulas que expresan vla-4.
|
|
BR112014017517A2
(pt)
|
2012-01-27 |
2017-06-13 |
Hoffmann La Roche |
composto, composição farmacêutica, método de tratamento de inflamações, uso de composto e invenção
|
|
EP2806899B1
(en)
|
2012-01-27 |
2016-10-19 |
F.Hoffmann-La Roche Ag |
Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3
|
|
AU2013222179B2
(en)
|
2012-02-24 |
2017-08-24 |
Arbutus Biopharma Corporat ion |
Trialkyl cationic lipids and methods of use thereof
|
|
CN102600173B
(zh)
*
|
2012-03-02 |
2013-05-29 |
海南美兰史克制药有限公司 |
氨氯地平/贝那普利药物组合物脂质体固体制剂
|
|
US10322089B2
(en)
*
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
|
WO2013143555A1
(en)
*
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
ES2858523T3
(es)
|
2012-03-29 |
2021-09-30 |
Translate Bio Inc |
Nanopartículas neutras derivadas de lípidos
|
|
BR112014024131A2
(pt)
|
2012-03-29 |
2017-07-25 |
Shire Human Genetic Therapies |
lipídios catiônicos ionizáveis
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
CN108949772A
(zh)
*
|
2012-04-02 |
2018-12-07 |
现代泰克斯公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
EP3520821A1
(en)
*
|
2012-04-02 |
2019-08-07 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9402816B2
(en)
|
2012-04-19 |
2016-08-02 |
Sima Therapeutics, Inc. |
Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery
|
|
EP2841572B1
(en)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetic correction of mutated genes
|
|
HK1208618A1
(en)
|
2012-06-08 |
2016-03-11 |
夏尔人类遗传性治疗公司 |
Pulmonary delivery of mrna to non-lung target cells
|
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
TW201726599A
(zh)
|
2012-07-06 |
2017-08-01 |
協和醱酵麒麟有限公司 |
陽離子性脂質
|
|
WO2014008334A1
(en)
|
2012-07-06 |
2014-01-09 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
CA2884870C
(en)
|
2012-08-13 |
2022-03-29 |
Massachusetts Institute Of Technology |
Amine-containing lipidoids and uses thereof
|
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
|
SI2922554T1
(sl)
|
2012-11-26 |
2022-06-30 |
Modernatx, Inc. |
Terminalno modificirana RNA
|
|
WO2014085526A1
(en)
|
2012-11-29 |
2014-06-05 |
Insmed Incorporated |
Stabilized vancomycin formulations
|
|
EP2929035A1
(en)
|
2012-12-07 |
2015-10-14 |
Shire Human Genetic Therapies, Inc. |
Lipidic nanoparticles for mrna delivering
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
MX393573B
(es)
|
2013-03-14 |
2025-03-21 |
Shire Human Genetic Therapies |
Composiciones de acido ribonucleico mensajero del regulador transmembrana de fibrosis quistica y metodos y usos relacionados
|
|
PL2970456T3
(pl)
|
2013-03-14 |
2022-01-31 |
Translate Bio, Inc. |
Sposoby i kompozycje do dostarczania przeciwciał kodowanych mrna
|
|
KR20150128687A
(ko)
|
2013-03-14 |
2015-11-18 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 정제 방법
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
EP3757570B1
(en)
|
2013-03-15 |
2023-10-11 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
WO2014179562A1
(en)
|
2013-05-01 |
2014-11-06 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
AU2014340149B2
(en)
|
2013-10-22 |
2020-12-24 |
Shire Human Genetic Therapies, Inc. |
CNS delivery of mRNA and uses thereof
|
|
EP3574923A1
(en)
|
2013-10-22 |
2019-12-04 |
Translate Bio, Inc. |
Mrna therapy for phenylketonuria
|
|
CA2928078A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Lipid formulations for delivery of messenger rna
|
|
JP6608815B2
(ja)
|
2013-10-22 |
2019-11-20 |
トランスレイト バイオ， インコーポレイテッド |
アルギニノコハク酸合成酵素欠損症のｍＲＮＡ治療
|
|
EP3985118A1
(en)
|
2013-11-22 |
2022-04-20 |
MiNA Therapeutics Limited |
C/ebp alpha short activating rna compositions and methods of use
|
|
AU2014383024B2
(en)
|
2013-12-03 |
2020-04-30 |
Exicure, Inc. |
Liposomal particles, methods of making same and uses thereof
|
|
CA2935914C
(en)
*
|
2014-01-09 |
2022-02-08 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
|
EP3110401A4
(en)
|
2014-02-25 |
2017-10-25 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
SI3122878T1
(sl)
|
2014-03-24 |
2019-05-31 |
Translate Bio, Inc. |
MRNA terapija za zdravljenje očesnih bolezni
|
|
MA58292B1
(fr)
|
2014-04-23 |
2025-01-31 |
Modernatx, Inc. |
Vaccins à base d'acide nucléique
|
|
EP3636742B1
(en)
|
2014-04-25 |
2025-11-05 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
KR102447412B1
(ko)
|
2014-05-15 |
2022-09-23 |
인스메드 인코포레이티드 |
폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법
|
|
CN105085295A
(zh)
*
|
2014-05-23 |
2015-11-25 |
上海交通大学 |
氨甲环酸的两亲性衍生物及其用途
|
|
CN105085292B
(zh)
*
|
2014-05-23 |
2017-12-15 |
上海交通大学 |
3‑((2‑(二甲氨基)乙烷基)(甲基)氨基)丙酸的两亲性衍生物及其用途
|
|
CA2949106C
(en)
|
2014-05-30 |
2023-10-24 |
Shire Human Genetic Therapies, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
EP3164113B1
(en)
|
2014-06-04 |
2019-03-27 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
|
KR102387898B1
(ko)
|
2014-06-24 |
2022-04-15 |
샤이어 휴먼 지네틱 테라피즈 인크. |
핵산의 전달용 입체화학적으로 풍부한 조성물
|
|
WO2015199952A1
(en)
|
2014-06-25 |
2015-12-30 |
Acuitas Therapeutics Inc. |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
AU2015285279A1
(en)
|
2014-06-30 |
2017-02-16 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
|
WO2016004318A1
(en)
|
2014-07-02 |
2016-01-07 |
Shire Human Genetic Therapies, Inc. |
Encapsulation of messenger rna
|
|
US9840479B2
(en)
|
2014-07-02 |
2017-12-12 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
|
GB201414464D0
(en)
|
2014-08-14 |
2014-10-01 |
Technion Res & Dev Foundation |
Compositions and methods for therapeutics prescreening
|
|
JP6797108B2
(ja)
|
2014-08-19 |
2020-12-09 |
ノースウェスタン ユニバーシティ |
タンパク質／オリゴヌクレオチドコアシェルナノ粒子治療薬
|
|
KR102410072B1
(ko)
|
2014-08-29 |
2022-06-20 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
|
|
MA56412A
(fr)
|
2014-12-05 |
2022-05-04 |
Translate Bio Inc |
Thérapie par l'arn messager pour le traitement des maladies articulaires
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
AU2016233135B2
(en)
|
2015-03-19 |
2021-07-08 |
Translate Bio, Inc. |
mRNA therapy for pompe disease
|
|
KR20170130531A
(ko)
*
|
2015-03-24 |
2017-11-28 |
교와 핫꼬 기린 가부시키가이샤 |
핵산 함유 지질 나노 입자
|
|
EP3283125B1
(en)
|
2015-04-17 |
2021-12-29 |
CureVac Real Estate GmbH |
Lyophilization of rna
|
|
CA2984125A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
CA2984512A1
(en)
|
2015-05-06 |
2016-11-10 |
Benitec Biopharma Limited |
Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
|
|
CN104803863B
(zh)
*
|
2015-05-08 |
2016-07-20 |
厦门成坤生物技术有限公司 |
阳离子类脂化合物及其制备方法
|
|
SG11201708541QA
(en)
|
2015-05-20 |
2017-12-28 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
CN107635587A
(zh)
|
2015-05-20 |
2018-01-26 |
库瑞瓦格股份公司 |
包含长链rna的干燥粉末组合物
|
|
WO2016205691A1
(en)
|
2015-06-19 |
2016-12-22 |
Massachusetts Institute Of Technology |
Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
|
|
HUE067372T2
(hu)
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
HRP20210543T1
(hr)
|
2015-07-07 |
2021-05-14 |
H. Lundbeck A/S |
Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti
|
|
WO2017008076A1
(en)
*
|
2015-07-09 |
2017-01-12 |
Insmed Incorporated |
Compositions and methods for treating lung diseases and lung injury
|
|
US11007260B2
(en)
|
2015-07-21 |
2021-05-18 |
Modernatx, Inc. |
Infectious disease vaccines
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
HUE051998T2
(hu)
|
2015-07-31 |
2021-04-28 |
Alnylam Pharmaceuticals Inc |
Transztiretin (TTR) iRNS készítmények és eljárások azok alkalmazása TTR-asszociált betegségek kezelésére vagy megelõzésére
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
CA2995995A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
|
JP6948313B6
(ja)
|
2015-09-17 |
2022-01-14 |
モデルナティエックス インコーポレイテッド |
治療剤の細胞内送達のための化合物および組成物
|
|
MX2018004043A
(es)
|
2015-10-02 |
2018-11-09 |
Complexa Inc |
Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados.
|
|
CA3001003A1
(en)
|
2015-10-05 |
2017-04-13 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
|
CN114686548A
(zh)
|
2015-10-14 |
2022-07-01 |
川斯勒佰尔公司 |
用于增强生产的rna相关酶的修饰
|
|
JP2018531290A
(ja)
|
2015-10-22 |
2018-10-25 |
モデルナティーエックス， インコーポレイテッド |
性感染症ワクチン
|
|
PL3718565T3
(pl)
|
2015-10-22 |
2022-09-19 |
Modernatx, Inc. |
Szczepionki przeciwko wirusom układu oddechowego
|
|
WO2017070613A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
EA201891001A1
(ru)
|
2015-10-22 |
2018-11-30 |
МОДЕРНАТиЭкс, ИНК. |
Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
|
|
IL286515B2
(en)
|
2015-10-28 |
2024-02-01 |
Acuitas Therapeutics Inc |
Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids
|
|
EA201891317A3
(ru)
|
2015-11-30 |
2019-04-30 |
Дьюк Юниверсити |
Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
|
|
SMT202200358T1
(it)
|
2015-12-10 |
2022-11-18 |
Modernatx Inc |
Composizioni e metodi di rilascio degli agenti terapeutici
|
|
CN106883158B
(zh)
*
|
2015-12-15 |
2019-08-23 |
中国科学院广州生物医药与健康研究院 |
生物可降解的氨基脂质类化合物及其制备方法和应用
|
|
EP3394030B2
(en)
|
2015-12-22 |
2025-02-12 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
CA3009131C
(en)
|
2015-12-25 |
2024-06-04 |
Kyowa Hakko Kirin Co., Ltd. |
Compounds as cationic lipids and their use in nucleic acid delivery compositions
|
|
CN105622473B
(zh)
*
|
2016-02-06 |
2017-07-25 |
吴国球 |
一种阳离子氨基脂质及其合成方法和用途
|
|
EP3436066A1
(en)
|
2016-04-01 |
2019-02-06 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
|
EP3440206B1
(en)
|
2016-04-08 |
2020-10-28 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
EP3443081A4
(en)
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
|
CN109219659B
(zh)
|
2016-04-14 |
2022-09-09 |
贝尼泰克生物制药有限公司 |
用于治疗眼咽型肌营养不良(opmd)的试剂及其用途
|
|
JP7186094B2
(ja)
|
2016-05-06 |
2022-12-08 |
イグジキュア オペレーティング カンパニー |
インターロイキン１７受容体ｍＲＮＡの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド（ＡＳＯ）を提示するリポソーム系球状核酸（ＳＮＡ）構築物
|
|
CN109414408B
(zh)
*
|
2016-05-16 |
2022-03-29 |
得克萨斯州大学系统董事会 |
阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
|
|
CA3024135C
(en)
*
|
2016-05-16 |
2024-09-24 |
Univ Texas |
Compositions intended for the administration of RNA in the form of nanoparticles and associated method of use
|
|
KR102533456B1
(ko)
|
2016-05-18 |
2023-05-17 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
AU2017283479B2
(en)
|
2016-06-13 |
2023-08-17 |
Translate Bio, Inc. |
Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
|
|
CA3020271A1
(en)
|
2016-06-24 |
2017-12-28 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
|
EP3478838A1
(en)
*
|
2016-06-30 |
2019-05-08 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger rna
|
|
EP4275747A3
(en)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
CN109715205A
(zh)
|
2016-08-19 |
2019-05-03 |
库瑞瓦格股份公司 |
用于癌症治疗的rna
|
|
CA3038480A1
(en)
|
2016-09-27 |
2018-04-05 |
Kyowa Hakko Kirin Co., Ltd. |
Compound usable as cationic lipid
|
|
WO2018062413A1
(ja)
*
|
2016-09-28 |
2018-04-05 |
協和発酵キリン株式会社 |
核酸含有脂質ナノ粒子
|
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
US20190314486A1
(en)
|
2016-10-21 |
2019-10-17 |
Merck Sharp & Dohme Corp. |
Influenza hemagglutinin protein vaccines
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
JP7738979B2
(ja)
|
2016-11-10 |
2025-09-16 |
トランスレイト バイオ， インコーポレイテッド |
Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス
|
|
CA3041350A1
(en)
|
2016-11-10 |
2018-05-17 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger rna
|
|
WO2018089851A2
(en)
|
2016-11-11 |
2018-05-17 |
Modernatx, Inc. |
Influenza vaccine
|
|
CN110582304A
(zh)
|
2016-12-08 |
2019-12-17 |
库尔维科公司 |
用于治疗或预防肝脏疾病的rna
|
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
|
US11542490B2
(en)
|
2016-12-08 |
2023-01-03 |
CureVac SE |
RNAs for wound healing
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
EP3558354A1
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Lassa virus vaccine
|
|
EP3558355A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Henipavirus vaccine
|
|
WO2018129544A1
(en)
|
2017-01-09 |
2018-07-12 |
Whitehead Institute For Biomedical Research |
Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
|
|
US11241490B2
(en)
|
2017-01-11 |
2022-02-08 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified RNA for inducing an immune response against zika virus
|
|
EP3582790A4
(en)
|
2017-02-16 |
2020-11-25 |
ModernaTX, Inc. |
VERY POWERFUL IMMUNOGENIC COMPOSITIONS
|
|
EP3585417B1
(en)
|
2017-02-27 |
2023-02-22 |
Translate Bio, Inc. |
Method of making a codon-optimized cftr mrna
|
|
WO2018165257A1
(en)
|
2017-03-07 |
2018-09-13 |
Translate Bio, Inc. |
Polyanionic delivery of nucleic acids
|
|
DK3596041T3
(da)
|
2017-03-15 |
2023-01-23 |
Modernatx Inc |
Forbindelse og sammensætninger til intracellulær afgivelse af terapeutiske midler
|
|
MA47787A
(fr)
|
2017-03-15 |
2020-01-22 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
MA52262A
(fr)
|
2017-03-15 |
2020-02-19 |
Modernatx Inc |
Vaccin à large spectre contre le virus de la grippe
|
|
WO2018170336A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
SI3596042T1
(sl)
|
2017-03-15 |
2022-04-29 |
Modernatx, Inc. |
Kristalne oblike amino lipidov
|
|
JP2020514370A
(ja)
|
2017-03-17 |
2020-05-21 |
キュアバック アーゲー |
組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤
|
|
US20200030432A1
(en)
|
2017-03-17 |
2020-01-30 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
EP3601576A1
(en)
|
2017-03-24 |
2020-02-05 |
CureVac AG |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
JP7464954B2
(ja)
|
2017-04-27 |
2024-04-10 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Ｃ型肝炎ウイルスに対するヌクレオシド修飾ｍＲＮＡ－脂質ナノ粒子系統ワクチン
|
|
ES2981244T3
(es)
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
|
US11433131B2
(en)
|
2017-05-11 |
2022-09-06 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (SNAs)
|
|
AU2018268859B2
(en)
|
2017-05-16 |
2024-07-25 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR
|
|
ES3039647T3
(en)
|
2017-05-31 |
2025-10-23 |
Arcturus Therapeutics Inc |
Synthesis and structure of high potency rna therapeutics
|
|
TWI794237B
(zh)
|
2017-05-31 |
2023-03-01 |
美商奧特吉尼克斯製藥公司 |
Iii 型糖原貯積病治療劑
|
|
US11939600B2
(en)
|
2017-05-31 |
2024-03-26 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating phenylketonuria
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
WO2018236849A1
(en)
|
2017-06-19 |
2018-12-27 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of friedreich's ataxia
|
|
BR112019028280A2
(pt)
|
2017-07-04 |
2020-07-14 |
Curevac Ag |
moléculas de ácido nucleico
|
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
|
US11633365B2
(en)
|
2017-08-04 |
2023-04-25 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticle
|
|
US11639329B2
(en)
|
2017-08-16 |
2023-05-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036000A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
|
CA3073211A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
WO2019048645A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
|
|
AU2018330494A1
(en)
|
2017-09-08 |
2020-03-26 |
Mina Therapeutics Limited |
HNF4a saRNA compositions and methods of use
|
|
WO2019055807A1
(en)
|
2017-09-14 |
2019-03-21 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZIKA VIRUS
|
|
WO2019060442A1
(en)
|
2017-09-19 |
2019-03-28 |
Alnylam Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF TRANSTHYRETIN MEDIATED AMYLOSIS (TTR)
|
|
US20220233568A1
(en)
|
2017-10-19 |
2022-07-28 |
Curevac Ag |
Novel artificial nucleic acid molecules
|
|
EP3707271A1
(en)
|
2017-11-08 |
2020-09-16 |
CureVac AG |
Rna sequence adaptation
|
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
|
MA51306A
(fr)
|
2017-12-20 |
2020-10-28 |
Translate Bio Inc |
Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
|
|
BR112020013201A2
(pt)
|
2017-12-27 |
2020-12-01 |
Takeda Pharmaceutical Company Limited |
nanopartícula lipídica, medicamento, métodos para expressar um receptor, para prevenir ou tratar câncer e para produzir um medicamento, uso da nanopartícula lipídica e do imunócito ex vivo, composição, imunócito ex vivo, e, célula ex vivo
|
|
CN111417621A
(zh)
|
2017-12-27 |
2020-07-14 |
卫材R&D管理有限公司 |
阳离子脂质
|
|
MA54676A
(fr)
|
2018-01-29 |
2021-11-17 |
Modernatx Inc |
Vaccins à base d'arn contre le vrs
|
|
CN111655715A
(zh)
|
2018-01-29 |
2020-09-11 |
默沙东公司 |
稳定化的rsv f蛋白及其用途
|
|
WO2019152802A1
(en)
|
2018-02-02 |
2019-08-08 |
Translate Bio, Inc. |
Cationic polymers
|
|
AU2019218557A1
(en)
*
|
2018-02-12 |
2020-08-20 |
Interna Technologies B.V. |
Anticancer microRNA and lipid formulations thereof
|
|
EP3752194A4
(en)
|
2018-02-13 |
2022-03-16 |
Checkmate Pharmaceuticals, Inc. |
ANTI-TUMOR IMMUNOTHERAPY COMPOSITIONS AND METHODS
|
|
JP7460534B2
(ja)
|
2018-03-30 |
2024-04-02 |
インスメッド インコーポレイテッド |
リポソーム医薬品の連続製造方法
|
|
EP3773702A2
(en)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
|
US12084655B2
(en)
|
2018-04-09 |
2024-09-10 |
Checkmate Pharmaceuticals |
Packaging oligonucleotides into virus-like particles
|
|
US11566246B2
(en)
|
2018-04-12 |
2023-01-31 |
Mina Therapeutics Limited |
SIRT1-saRNA compositions and methods of use
|
|
CN112292395A
(zh)
|
2018-04-17 |
2021-01-29 |
库瑞瓦格股份公司 |
用于疫苗接种的新型rsv rna分子和组合物
|
|
AU2019271132A1
(en)
|
2018-05-15 |
2020-11-12 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger RNA
|
|
AU2019271215B2
(en)
|
2018-05-16 |
2024-09-12 |
Translate Bio, Inc. |
Ribose cationic lipids
|
|
JP7488193B2
(ja)
|
2018-05-24 |
2024-05-21 |
トランスレイト バイオ， インコーポレイテッド |
チオエステルカチオン性脂質
|
|
CN112469413B
(zh)
|
2018-05-25 |
2024-01-12 |
伊马拉公司 |
6-[(3s,4s)-4-甲基-1-(嘧啶-2-基甲基)吡咯烷-3-基]-3-四氢吡喃-4-基-7h-咪唑并[1,5-a]吡嗪-8-酮的一水合物和结晶形态
|
|
MA52766A
(fr)
|
2018-05-30 |
2021-04-14 |
Translate Bio Inc |
Lipides cationiques vitaminiques
|
|
WO2019232208A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Cationic lipids comprising a steroidal moiety
|
|
AU2019277361B2
(en)
|
2018-05-30 |
2025-04-24 |
Translate Bio, Inc. |
Messenger RNA vaccines and uses thereof
|
|
CA3101484A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
CN120514877A
(zh)
|
2018-07-23 |
2025-08-22 |
川斯勒佰尔公司 |
信使rna的干粉制剂
|
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
|
WO2020047061A1
(en)
|
2018-08-29 |
2020-03-05 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
EP3843737A4
(en)
|
2018-08-31 |
2022-06-01 |
Imara Inc. |
PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
|
|
US20230145188A1
(en)
|
2018-09-14 |
2023-05-11 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
|
WO2020061284A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
JP7640452B2
(ja)
|
2018-09-19 |
2025-03-05 |
モデルナティエックス インコーポレイテッド |
高純度ｐｅｇ脂質及びそれらの使用
|
|
US12263248B2
(en)
|
2018-09-19 |
2025-04-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
US12329857B2
(en)
|
2018-09-21 |
2025-06-17 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
AU2019351809C1
(en)
|
2018-10-01 |
2025-09-11 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
CA3114699A1
(en)
|
2018-10-09 |
2020-04-16 |
The University Of British Columbia |
Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
|
|
KR20210080435A
(ko)
|
2018-10-18 |
2021-06-30 |
다케다 야쿠힌 고교 가부시키가이샤 |
T 세포의 활성화/증식을 위한 방법
|
|
CA3112837A1
(en)
|
2018-10-19 |
2020-04-23 |
Translate Bio, Inc. |
Pumpless encapsulation of messenger rna
|
|
CA3117866A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
|
KR20210105888A
(ko)
*
|
2018-11-09 |
2021-08-27 |
아뷰터스 바이오파마 코포레이션 |
규소를 포함하는 양이온성 지질
|
|
US20220016265A1
(en)
|
2018-11-09 |
2022-01-20 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
|
JP7483294B2
(ja)
|
2018-11-09 |
2024-05-15 |
トランスレイト バイオ， インコーポレイテッド |
層間エステル、チオエステル、ジスルフィドおよび無水部分を含む２，５－ジオキソピペラジン脂質
|
|
AU2019374871B2
(en)
|
2018-11-09 |
2025-09-11 |
Translate Bio, Inc. |
PEG lipidoid compounds
|
|
CA3119449A1
(en)
|
2018-11-12 |
2020-05-22 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
|
WO2020106946A1
(en)
|
2018-11-21 |
2020-05-28 |
Translate Bio, Inc. |
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
|
|
EP3883917B1
(en)
|
2018-11-21 |
2024-01-24 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
|
|
US11685906B2
(en)
|
2018-12-06 |
2023-06-27 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating ornithine transcarbamylase deficiency
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
WO2020128031A2
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Rna for malaria vaccines
|
|
EP3908597A1
(en)
|
2019-01-07 |
2021-11-17 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
JP7523449B2
(ja)
|
2019-01-11 |
2024-07-26 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
EP4427739A3
(en)
*
|
2019-01-31 |
2024-10-16 |
ModernaTX, Inc. |
Methods of preparing lipid nanoparticles
|
|
US20220133908A1
(en)
|
2019-02-08 |
2022-05-05 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
MA55321A
(fr)
|
2019-03-15 |
2022-01-19 |
Modernatx Inc |
Vaccins à base d'arn contre le vih
|
|
EP3947646A1
(en)
|
2019-04-05 |
2022-02-09 |
Precision BioSciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
EP3953473A1
(en)
|
2019-04-12 |
2022-02-16 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
US20220177423A1
(en)
|
2019-04-18 |
2022-06-09 |
Translate Bio, Inc. |
Cystine cationic lipids
|
|
ES2972014T3
(es)
|
2019-04-22 |
2024-06-10 |
Translate Bio Inc |
Lípidos catiónicos de tioéster
|
|
EP3962902A1
(en)
|
2019-05-03 |
2022-03-09 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
|
KR20220024022A
(ko)
|
2019-05-14 |
2022-03-03 |
트랜슬레이트 바이오 인코포레이티드 |
Mrna-로딩된 지질 나노입자를 제조하는 개선된 방법
|
|
EP3972653A1
(en)
|
2019-05-22 |
2022-03-30 |
Massachusetts Institute of Technology |
Circular rna compositions and methods
|
|
US20220226244A1
(en)
|
2019-05-31 |
2022-07-21 |
Translate Bio, Inc. |
Macrocyclic lipids
|
|
US20220313813A1
(en)
|
2019-06-18 |
2022-10-06 |
Curevac Ag |
Rotavirus mrna vaccine
|
|
WO2020257716A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Tricine and citric acid lipids
|
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
|
MX2022000183A
(es)
*
|
2019-07-03 |
2022-05-20 |
Factor Bioscience Inc |
Lipidos cationicos y usos de estos.
|
|
KR20220078557A
(ko)
|
2019-07-08 |
2022-06-10 |
트랜슬레이트 바이오 인코포레이티드 |
개선된 mrna 로딩된 지질 나노입자 및 이의 제조 방법
|
|
CA3147875A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
|
JP7630904B2
(ja)
*
|
2019-07-23 |
2025-02-18 |
株式会社東芝 |
核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
|
|
JP7764363B2
(ja)
|
2019-07-23 |
2025-11-05 |
トランスレイト バイオ， インコーポレイテッド |
ｍＲＮＡ担持脂質ナノ粒子の安定性組成物および作製のプロセス
|
|
US20220323542A1
(en)
|
2019-07-30 |
2022-10-13 |
Translate Bio, Inc. |
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
|
|
US10501404B1
(en)
|
2019-07-30 |
2019-12-10 |
Factor Bioscience Inc. |
Cationic lipids and transfection methods
|
|
AU2020328855A1
(en)
|
2019-08-14 |
2022-03-03 |
CureVac SE |
RNA combinations and compositions with decreased immunostimulatory properties
|
|
KR20220101077A
(ko)
|
2019-09-19 |
2022-07-19 |
모더나티엑스, 인크. |
치료제의 세포내 전달을 위한 분지형 꼬리 지질 화합물 및 조성물
|
|
CA3155003A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
CN114391040A
(zh)
|
2019-09-23 |
2022-04-22 |
欧米茄治疗公司 |
用于调节载脂蛋白b(apob)基因表达的组合物和方法
|
|
AU2020352552A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
|
|
JP7650873B2
(ja)
|
2019-10-09 |
2025-03-25 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａの組成物、方法および使用
|
|
CA3155074A1
(en)
*
|
2019-10-18 |
2021-04-22 |
The Trustees Of The University Of Pennsylvania |
Lipid and lipid nanoparticle formulation for drug delivery
|
|
US20210145860A1
(en)
|
2019-10-21 |
2021-05-20 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
|
CN115052635B
(zh)
|
2019-12-04 |
2025-07-22 |
奥纳治疗公司 |
环状rna组合物和方法
|
|
CN114901360A
(zh)
|
2019-12-20 |
2022-08-12 |
库瑞瓦格股份公司 |
用于递送核酸的新型脂质纳米颗粒
|
|
KR20220142432A
(ko)
|
2019-12-20 |
2022-10-21 |
트랜슬레이트 바이오 인코포레이티드 |
메신저 rna의 직장 전달
|
|
CA3165388A1
(en)
|
2019-12-20 |
2021-06-24 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
EP3886897A1
(en)
|
2020-02-04 |
2021-10-06 |
CureVac AG |
Coronavirus vaccine
|
|
TW202140069A
(zh)
|
2020-02-14 |
2021-11-01 |
美商默沙東藥廠 |
Hpv疫苗
|
|
US11969480B2
(en)
|
2020-02-25 |
2024-04-30 |
Translate Bio, Inc. |
Processes of preparing mRNA-loaded lipid nanoparticles
|
|
US12351834B2
(en)
|
2020-03-03 |
2025-07-08 |
Arcturus Therapeutics, Inc. |
Compositions and methods for the treatment of ornithine transcarbamylase deficiency
|
|
TW202200605A
(zh)
|
2020-03-09 |
2022-01-01 |
美商亞克圖羅斯醫療公司 |
冠狀病毒疫苗組成物和方法
|
|
WO2021183720A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
CA3172591A1
(en)
|
2020-03-24 |
2021-09-30 |
Douglas Anthony KERR |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
KR20230003477A
(ko)
|
2020-03-24 |
2023-01-06 |
제너레이션 바이오 컴퍼니 |
비-바이러스성 dna 벡터 및 인자 ix 치료제 발현을 위한 이의 용도
|
|
FI20215508A1
(en)
|
2020-04-09 |
2021-10-10 |
Niemelae Erik Johan |
Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
CA3176844A1
(en)
|
2020-05-01 |
2021-11-04 |
Carlos G. PEREZ-GARCIA |
Nucleic acids and methods of treatment for cystic fibrosis
|
|
CA3177940A1
(en)
|
2020-05-07 |
2021-11-11 |
Anusha DIAS |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
|
WO2021226463A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
WO2021226468A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
|
EP4149556A1
(en)
|
2020-05-14 |
2023-03-22 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
CN115916158A
(zh)
|
2020-05-15 |
2023-04-04 |
翻译生物公司 |
用于mRNA递送的脂质纳米颗粒配制品
|
|
BR112022023554A2
(pt)
|
2020-05-19 |
2023-04-11 |
Orna Therapeutics Inc |
Composições e métodos de rna circular
|
|
TW202208629A
(zh)
|
2020-05-20 |
2022-03-01 |
美商旗艦先鋒創新有限責任公司 |
免疫原性組成物及其用途
|
|
AU2021275223A1
(en)
|
2020-05-20 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc. |
Coronavirus antigen compositions and their uses
|
|
WO2021239880A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
AU2021281453A1
(en)
|
2020-05-29 |
2022-11-17 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
EP4158031A1
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
|
US20240307556A1
(en)
|
2020-07-02 |
2024-09-19 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
|
PH12023550030A1
(en)
|
2020-07-08 |
2024-03-11 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
CN116096702A
(zh)
|
2020-07-16 |
2023-05-09 |
爱康泰生治疗公司 |
用于脂质纳米颗粒的阳离子脂质
|
|
US20230272432A1
(en)
|
2020-07-27 |
2023-08-31 |
Anjarium Biosciences Ag |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
|
CA3170741A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
MX2023001567A
(es)
*
|
2020-08-06 |
2023-06-28 |
Modernatx Inc |
Metodos de preparacion de nanoparticulas lipidicas.
|
|
JP2023537609A
(ja)
|
2020-08-14 |
2023-09-04 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
脂質ナノ粒子を凍結乾燥する方法
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
CA3170743A1
(en)
|
2020-08-31 |
2022-03-03 |
Susanne RAUCH |
Multivalent nucleic acid based coronavirus vaccines
|
|
CA3193746A1
(en)
|
2020-09-03 |
2022-03-10 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
US20230372440A1
(en)
|
2020-10-06 |
2023-11-23 |
Translate Bio, Inc. |
Improved process and formulation of lipid nanoparticles
|
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
WO2022081544A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
US20220133631A1
(en)
|
2020-10-12 |
2022-05-05 |
Translate Bio, Inc. |
Process of preparing ice-based lipid nanoparticles
|
|
IL301890A
(en)
|
2020-10-14 |
2023-06-01 |
George Mason Res Foundation Inc |
Ionizable lipids and methods of manufacture and use thereof
|
|
EP4240326A1
(en)
|
2020-11-09 |
2023-09-13 |
Translate Bio, Inc. |
Improved compositions for delivery of codon-optimized mrna
|
|
CA3200234A1
(en)
|
2020-11-25 |
2022-06-02 |
Daryl C. Drummond |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
|
EP4251129A1
(en)
|
2020-11-25 |
2023-10-04 |
Translate Bio, Inc. |
Stable liquid lipid nanoparticle formulations
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
MX2023007630A
(es)
|
2020-12-23 |
2023-08-25 |
Flagship Pioneering Innovations Vi Llc |
Composiciones de trem modificadas y usos de las mismas.
|
|
AU2021412833A1
(en)
|
2020-12-28 |
2023-07-06 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
EP4277929A1
(en)
|
2021-01-14 |
2023-11-22 |
Translate Bio, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
|
CA3170747A1
(en)
|
2021-01-27 |
2022-08-04 |
Moritz THRAN |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
EP4313115A1
(en)
|
2021-03-25 |
2024-02-07 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
|
KR20230160872A
(ko)
|
2021-03-26 |
2023-11-24 |
미나 테라퓨틱스 리미티드 |
Tmem173 sarna 조성물 및 사용 방법
|
|
US20240181038A1
(en)
|
2021-03-26 |
2024-06-06 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
KR20230165276A
(ko)
|
2021-03-31 |
2023-12-05 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
|
|
US20250345524A1
(en)
|
2021-03-31 |
2025-11-13 |
CureVac SE |
Syringes containing pharmaceutical compositions comprising rna
|
|
JP2024515668A
(ja)
|
2021-04-19 |
2024-04-10 |
トランスレイト バイオ， インコーポレイテッド |
Ｍｒｎａの送達のための改善された組成物
|
|
KR20240012370A
(ko)
|
2021-04-20 |
2024-01-29 |
안자리움 바이오사이언시스 아게 |
아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
KR20240011714A
(ko)
|
2021-04-27 |
2024-01-26 |
제너레이션 바이오 컴퍼니 |
치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
|
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
|
EP4347577A4
(en)
*
|
2021-05-28 |
2025-09-03 |
Nanovation Therapeutics Inc |
KC2-TYPE LIPIDS
|
|
EP4353268A1
(en)
|
2021-06-11 |
2024-04-17 |
Nibec Co., Ltd. |
Nanoparticle comprising peptide-lipid conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same
|
|
EP4362920A1
(en)
|
2021-07-01 |
2024-05-08 |
Translate Bio, Inc. |
Compositions for delivery of mrna
|
|
EP4362957A1
(en)
|
2021-07-01 |
2024-05-08 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
US20240336945A1
(en)
|
2021-07-26 |
2024-10-10 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
WO2023006999A2
(en)
|
2021-07-30 |
2023-02-02 |
CureVac SE |
Mrnas for treatment or prophylaxis of liver diseases
|
|
CA3227105A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
JP2024530018A
(ja)
|
2021-08-03 |
2024-08-14 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
トランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物およびその使用方法
|
|
AR126813A1
(es)
|
2021-08-19 |
2023-11-15 |
Merck Sharp & Dohme Llc |
Nueva nanopartícula lipídica termostable y métodos de uso de la misma
|
|
CN113461577B
(zh)
*
|
2021-09-01 |
2021-12-14 |
中山大学附属第七医院(深圳) |
一种氨基脂质及其应用
|
|
AU2022336664A1
(en)
|
2021-09-03 |
2024-01-18 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
JP2024538489A
(ja)
|
2021-09-03 |
2024-10-23 |
キュアバック エスイー |
核酸を送達するための新規な脂質ナノ粒子
|
|
CN115745942B
(zh)
*
|
2021-09-03 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115745941B
(zh)
*
|
2021-09-03 |
2025-07-01 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115772089B
(zh)
*
|
2021-09-07 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
JP2024534428A
(ja)
|
2021-09-17 |
2024-09-20 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
環状ポリリボヌクレオチドを生成するための組成物及び方法
|
|
CA3235625A1
(en)
|
2021-10-18 |
2023-04-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
MX2024005521A
(es)
|
2021-11-08 |
2024-05-21 |
Orna Therapeutics Inc |
Composiciones de nanoparticulas de lipidos para la administracion de polinucleotidos circulares.
|
|
CN118591398A
(zh)
|
2021-11-10 |
2024-09-03 |
翻译生物公司 |
用于治疗原发性纤毛运动不良症的组合物和方法
|
|
CN118900845A
(zh)
|
2021-11-24 |
2024-11-05 |
旗舰创业创新六公司 |
冠状病毒免疫原组合物及其用途
|
|
WO2023097003A2
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and their uses
|
|
JP2024541466A
(ja)
|
2021-11-24 |
2024-11-08 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
水痘帯状疱疹ウイルス免疫原組成物及びその使用
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
EP4448485A2
(en)
|
2021-12-16 |
2024-10-23 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
KR20240118174A
(ko)
|
2021-12-17 |
2024-08-02 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변성 조건 하에서의 원형 rna의 풍부화를 위한 방법
|
|
CN118679254A
(zh)
|
2021-12-22 |
2024-09-20 |
旗舰创业创新六公司 |
用于纯化多核糖核苷酸的组合物和方法
|
|
AU2022420620A1
(en)
|
2021-12-23 |
2024-07-04 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4463475A2
(en)
|
2022-01-14 |
2024-11-20 |
Anjarium Biosciences AG |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
US20250144235A1
(en)
|
2022-02-02 |
2025-05-08 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
JP2025509607A
(ja)
|
2022-03-14 |
2025-04-11 |
ジェネレーション バイオ カンパニー |
異種プライムブーストワクチン組成物及び使用の方法
|
|
KR20240166554A
(ko)
|
2022-03-25 |
2024-11-26 |
세일 바이오메디슨스, 인크. |
신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
|
|
WO2023190170A1
(ja)
*
|
2022-03-28 |
2023-10-05 |
日油株式会社 |
核酸内封脂質ナノ粒子の製造方法及びこれを含む医薬品組成物の製造方法、並びに、核酸を細胞内又は標的細胞内に導入する方法
|
|
CN119654166A
(zh)
|
2022-04-01 |
2025-03-18 |
内诺维什疗法股份有限公司 |
mRNA递送方法及其组合物
|
|
EP4504252A2
(en)
|
2022-04-08 |
2025-02-12 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
WO2023214405A1
(en)
|
2022-05-01 |
2023-11-09 |
Yeda Research And Development Co. Ltd. |
Reexpression of hnf4a to alleviate cancer-associated cachexia
|
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
JP2025516638A
(ja)
|
2022-05-13 |
2025-05-30 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
二本鎖ｄｎａ組成物及び関連する方法
|
|
KR20250028547A
(ko)
|
2022-05-25 |
2025-02-28 |
큐어백 에스이 |
대장균 FimH 항원성 폴리펩타이드를 인코딩하는 핵산 기반 백신
|
|
US12064479B2
(en)
|
2022-05-25 |
2024-08-20 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
CA3258303A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co |
Compositions of lipid nanoparticles and their uses
|
|
TW202423482A
(zh)
|
2022-06-08 |
2024-06-16 |
美商泰德治療公司 |
可電離陽離子脂質和脂質奈米顆粒、及其合成方法和用途
|
|
EP4544043A1
(en)
|
2022-06-22 |
2025-04-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
AU2023289696A1
(en)
|
2022-06-24 |
2025-01-16 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
AU2023320333A1
(en)
|
2022-08-01 |
2025-01-16 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
TW202426641A
(zh)
|
2022-08-19 |
2024-07-01 |
美商圖恩療法股份有限公司 |
以靶向基因抑制來調節b型肝炎病毒之組合物、系統和方法
|
|
JP2025530781A
(ja)
|
2022-08-31 |
2025-09-17 |
セイル バイオメディシンズ インコーポレイテッド |
新規のイオン化可能な脂質および脂質ナノ粒子ならびにそれらの使用方法
|
|
JPWO2024053648A1
(enExample)
|
2022-09-06 |
2024-03-14 |
|
|
|
JP2025531268A
(ja)
|
2022-09-19 |
2025-09-19 |
チューン セラピューティクス インコーポレイテッド |
Ｔ細胞機能を調節するための組成物、システム、および方法
|
|
KR20250075664A
(ko)
|
2022-09-26 |
2025-05-28 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
인플루엔자 바이러스 백신
|
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
|
AU2023368775A1
(en)
*
|
2022-10-25 |
2025-05-08 |
Nanovation Therapeutics Inc. |
Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
|
|
US12186389B2
(en)
|
2022-10-28 |
2025-01-07 |
Glaxosmithkline Biologicals Sa |
Nucleic acid base vaccine against emerging SARS-CoV-2 variants
|
|
KR20250099195A
(ko)
|
2022-10-31 |
2025-07-01 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
|
|
CN120390656A
(zh)
|
2022-11-08 |
2025-07-29 |
欧纳医疗公司 |
环状rna组合物
|
|
CN120435298A
(zh)
|
2022-11-08 |
2025-08-05 |
旗舰创业创新第六有限责任公司 |
用于产生环状多核糖核苷酸的组合物和方法
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
EP4622630A1
(en)
|
2022-11-21 |
2025-10-01 |
Translate Bio, Inc. |
Compositions of dry powder formulations of messenger rna and methods of use thereof
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
KR20250131271A
(ko)
|
2022-12-01 |
2025-09-02 |
제너레이션 바이오 컴퍼니 |
신규한 폴리글리세롤-접합된 지질 및 이를 포함하는 지질 나노입자 조성물
|
|
EP4626401A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
|
WO2024119039A2
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticles and uses thereof
|
|
KR20240087590A
(ko)
|
2022-12-09 |
2024-06-19 |
서울대학교산학협력단 |
B 세포 및 T 세포 내로 mRNA를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이의 용도
|
|
CN120615126A
(zh)
|
2022-12-09 |
2025-09-09 |
武田药品工业株式会社 |
经修饰的免疫调节剂
|
|
WO2024123139A1
(ko)
|
2022-12-09 |
2024-06-13 |
주식회사 나이벡 |
타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
|
|
WO2024129988A1
(en)
|
2022-12-14 |
2024-06-20 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for delivery of therapeutic agents to bone
|
|
EP4634388A1
(en)
|
2022-12-14 |
2025-10-22 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
EP4634390A2
(en)
|
2022-12-15 |
2025-10-22 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
AU2023394992A1
(en)
|
2022-12-15 |
2025-07-31 |
Sanofi Pasteur Inc. |
Mrna encoding influenza virus-like particle
|
|
WO2024133515A1
(en)
|
2022-12-20 |
2024-06-27 |
Sanofi |
Rhinovirus mrna vaccine
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
WO2024141786A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Multitarget vaccines and therapeutics
|
|
WO2024141784A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Broadly protective betacoronavirus vaccines and compositions
|
|
US12410394B2
(en)
*
|
2023-01-06 |
2025-09-09 |
Athergen, Inc. |
Composition comprising nicotinamide mononucleotide and leucomethylene blue
|
|
EP4648794A2
(en)
|
2023-01-09 |
2025-11-19 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
AU2024214423A1
(en)
|
2023-02-03 |
2025-09-18 |
Genzyme Corporation |
Hsc-specific antibody conjugated lipid nanoparticles and uses thereof
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
WO2024165974A1
(en)
*
|
2023-02-09 |
2024-08-15 |
Seqirus Inc. |
Ionizable cationic compound
|
|
WO2024173307A2
(en)
|
2023-02-13 |
2024-08-22 |
Flagship Pioneering Innovation Vii, Llc |
Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
US20240285805A1
(en)
|
2023-02-17 |
2024-08-29 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified uracil
|
|
IL322378A
(en)
|
2023-02-17 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
DNA compositions containing modified cytosine
|
|
KR20250153298A
(ko)
|
2023-03-08 |
2025-10-24 |
큐어백 에스이 |
핵산 전달을 위한 신규의 지질 나노입자 제형
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
WO2024192420A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024200823A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
|
|
WO2024200826A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
|
|
AR132276A1
(es)
|
2023-04-07 |
2025-06-11 |
Takeda Pharmaceuticals Co |
Complejo de conjugación
|
|
AU2024252590A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
AU2024255972A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
WO2024218166A1
(en)
|
2023-04-17 |
2024-10-24 |
Sanofi |
Reconstitutable dry powder formulations and methods of use thereof
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
TW202509222A
(zh)
|
2023-05-08 |
2025-03-01 |
美商默沙東有限責任公司 |
編碼諾羅病毒vp1抗原之多核苷酸及其用途
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
|
WO2024236361A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for delivery of nucleic acids to cells
|
|
WO2024236504A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Sequences and methods for delivery of dna and rna
|
|
CN116270543B
(zh)
*
|
2023-05-19 |
2023-09-26 |
清华大学 |
脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2024254226A1
(en)
|
2023-06-09 |
2024-12-12 |
Merck Sharp & Dohme Llc |
Nanoemulsion adjuvant compositions for human papillomavirus vaccines
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025008774A1
(en)
|
2023-07-05 |
2025-01-09 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
TW202515531A
(zh)
|
2023-07-07 |
2025-04-16 |
美商輝瑞股份有限公司 |
兩親性ｔｌｒ７／８佐劑及其用途
|
|
TW202516001A
(zh)
|
2023-07-25 |
2025-04-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
Ｃａｓ內切酶及相關方法
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
US20250243274A1
(en)
*
|
2023-07-31 |
2025-07-31 |
Jibe Therapeutics, Inc. |
Compositions for Redirecting Immunoglobulins to Immune Cells
|
|
WO2025027116A1
(en)
|
2023-08-01 |
2025-02-06 |
Institut Curie |
Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025064475A2
(en)
|
2023-09-18 |
2025-03-27 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025063214A1
(ja)
*
|
2023-09-22 |
2025-03-27 |
国立大学法人東北大学 |
核酸を内封したリガンド修飾脂質ナノ粒子の製造方法
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
US20250162981A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
TW202523695A
(zh)
|
2023-11-22 |
2025-06-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於治療非酒精性脂肪性肝病之方法及組成物
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025129128A1
(en)
|
2023-12-15 |
2025-06-19 |
Vivasor, Inc. |
Compositions and methods for non-viral delivery of therapeutic compounds
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025133115A1
(en)
|
2023-12-21 |
2025-06-26 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising il-35
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025180874A1
(en)
*
|
2024-02-27 |
2025-09-04 |
Basf Se |
Substituted 1,3-dioxolane sulfates and their use
|
|
WO2025190300A1
(zh)
*
|
2024-03-13 |
2025-09-18 |
仁景(苏州)生物科技有限公司 |
脂质纳米颗粒及脂质纳米颗粒组合物
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025196065A1
(en)
|
2024-03-20 |
2025-09-25 |
Sanofi |
Novel homocysteine based lipids and their use for delivery of nucleic acids
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|